Abstract
Previously we have reported 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1hpyrazole- 1-carboxamides as a novel class of antidepressants. The aim of the current study is to proposing the reason for such biological activities of the molecules by using molecular docking studies using AutoDock4.2. Using molecular docking studies, we propose that most of the antidepressant molecules showed good binding affinity towards MAO-A than MAO-B which is an effective target for the treatment of depression. The R and S form of thiophene based pyrazolines-carboxamides showed a binding energy and inhibition constant between 7.93 to -8.76 and 1.54 to 0.38 μM toward MAO-A and -6.39 to -8.51 and 20.84 to 0.57 μM toward MAO-B respectively.
Keywords: Antidepressant, pyrazoline, molecular docking, monoamine oxidase.
Central Nervous System Agents in Medicinal Chemistry
Title:Molecular Docking Studies of Some Novel Antidepressant 5-Substituted Phenyl-3-(Thiophen-2-yl)-4, 5-Dihydro-1h-Pyrazole-1-Carboxamides Against Monoamine Oxidase Isoforms
Volume: 16 Issue: 2
Author(s): Bijo Mathew, Jerad Suresh, Sockalingam Anbazhagan and Sanal Dev
Affiliation:
Keywords: Antidepressant, pyrazoline, molecular docking, monoamine oxidase.
Abstract: Previously we have reported 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1hpyrazole- 1-carboxamides as a novel class of antidepressants. The aim of the current study is to proposing the reason for such biological activities of the molecules by using molecular docking studies using AutoDock4.2. Using molecular docking studies, we propose that most of the antidepressant molecules showed good binding affinity towards MAO-A than MAO-B which is an effective target for the treatment of depression. The R and S form of thiophene based pyrazolines-carboxamides showed a binding energy and inhibition constant between 7.93 to -8.76 and 1.54 to 0.38 μM toward MAO-A and -6.39 to -8.51 and 20.84 to 0.57 μM toward MAO-B respectively.
Export Options
About this article
Cite this article as:
Mathew Bijo, Suresh Jerad, Anbazhagan Sockalingam and Dev Sanal, Molecular Docking Studies of Some Novel Antidepressant 5-Substituted Phenyl-3-(Thiophen-2-yl)-4, 5-Dihydro-1h-Pyrazole-1-Carboxamides Against Monoamine Oxidase Isoforms, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1871524915666150216123707
DOI https://dx.doi.org/10.2174/1871524915666150216123707 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Teenage-pregnancies from a Human Life History Viewpoint – an Updated Review with Special Respect to Prevention Strategies
Current Women`s Health Reviews Milestones in CRH Research
Current Molecular Pharmacology Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Protective Effect of Schizolobium parahyba Flavonoids Against Snake Venoms and Isolated Toxins
Current Topics in Medicinal Chemistry Cell Surface Markers on Adipose-Derived Stem Cells: A Systematic Review
Current Stem Cell Research & Therapy Impaired Quality Control of Mitochondria Underlying the Pathogenesis of Alzheimer's Disease
Current Drug Targets Should Adolescents be Screened for Depression?
Adolescent Psychiatry A Concept of Homeostatic Inflammation Provided by Endogenous TLR4 Agonists that Function Before and After Danger Signal for Metastasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Unraveling the Structural Requirements of Chalcone Chemistry Towards Monoamine Oxidase Inhibition
Central Nervous System Agents in Medicinal Chemistry Basic Symptoms and the Prediction of First-Episode Psychosis
Current Pharmaceutical Design Mitochondrion of Protozoan Parasite Emerges as Potent Therapeutic Target:Exciting Drugs are on the Horizon
Current Pharmaceutical Design Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry Editorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders
Current Alzheimer Research Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Current Alzheimer Research Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Common Treatment of Polycystic Ovarian Syndrome and Major Depressive Disorder: Case Report and Review
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Current Alzheimer Research